Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 12/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 12/20 | 0.81 |
| ▸ | GAA | P10253 | 3/20 | 0.81 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.81 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.81 |
| ▸ | POLB | P06746 | 1/20 | 0.81 |
| ▸ | ATM | Q13315 | 1/20 | 0.76 |
| ▸ | MAPT | P10636 | 6/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | TP53 | P04637 | 2/20 | 0.69 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.69 |
| ▸ | GBA1 | P04062 | 1/20 | 0.69 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1083776 | 0.86 | MEN1 (1.00) | MEN1KMT2AGAAALKNTRK1 | |
| SCHEMBL1084181 | 0.83 | KMT2A (0.72) | MEN1KMT2AGAAALKNTRK1 | |
| SCHEMBL2296472 | 0.82 | ABCG2 (0.74) | MEN1KMT2AGAAMAPTLMNA | |
| SCHEMBL22201364 | 0.82 | ABCG2 (0.94) | MEN1KMT2AGAAMAPTLMNA | |
| SCHEMBL8095812 | 0.82 | ABCG2 (1.00) | MEN1KMT2AGAAMAPTLMNA | |
| SCHEMBL1084165 | 0.80 | CYP1A2 (0.70) | MEN1KMT2AGAAALKNTRK1 | |
| SCHEMBL1083806 | 0.80 | MEN1 (0.71) | MEN1KMT2AGAAALKNTRK1 | |
| SCHEMBL5531993 | 0.79 | ABCG2 (0.89) | MEN1KMT2APOLBMAPTLMNA | |
| SCHEMBL2913682 | 0.79 | ABCG2 (0.69) | MEN1KMT2AMAPTLMNATP53 | |
| SCHEMBL801777 | 0.78 | GSK3A (0.72) | MEN1KMT2AGAAALKNTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343980-B2 | Quinazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-01 | — | — | US | disclosed |
| US-8343980-B2 | Quinazoles useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-01 | — | — | US | disclosed |
| US-8263642-B2 | Antimicrobial compounds and methods of use thereof | VANDERBILT UNIVERSITY (US) | 2012-09-11 | — | — | US | disclosed |
| US-8263642-B2 | Antimicrobial compounds and methods of use thereof | VANDERBILT UNIVERSITY (US) | 2012-09-11 | — | — | US | disclosed |
| US-8153642-B2 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153642-B2 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-10 | — | — | US | disclosed |
| US-7713983-B2 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713983-B2 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-05-11 | — | — | US | disclosed |
| US-7678802-B2 | Quinazolines useful as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-03-16 | — | — | US | disclosed |
| US-20100004324-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE THEREOF | VANDERBILT UNIVERSITY | 2010-01-07 | — | — | US | disclosed |
| US-20100004324-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE THEREOF | VANDERBILT UNIVERSITY | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004324-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF USE THEREOF | HMOX1, HMOX2, NOD2 | MEN1 4247/4885KMT2A 4544/4885GAA 1354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.